Rift Valley fever
ICD-10 A82.1 is a billable code used to indicate a diagnosis of rift valley fever.
Rift Valley fever (RVF) is a viral zoonotic disease caused by the Rift Valley fever virus (RVFV), primarily transmitted to humans through contact with infected animals or their bodily fluids. The disease is endemic in parts of Africa and the Arabian Peninsula, with outbreaks often linked to heavy rainfall and flooding, which increase mosquito populations. Clinically, RVF can present with a range of symptoms, from mild flu-like manifestations to severe complications such as hemorrhagic fever, encephalitis, and neurological disorders. Neurological complications, although less common, can include seizures, confusion, and other central nervous system (CNS) manifestations due to viral invasion. Vaccination against RVF is available and recommended for individuals at high risk, such as those working in veterinary medicine or in endemic areas. The disease's potential for severe outcomes and its zoonotic nature necessitate careful documentation and coding to ensure accurate representation of the patient's condition and treatment.
Detailed clinical notes on symptoms, exposure history, and laboratory results.
Patients presenting with fever, headache, and history of travel to endemic areas.
Ensure documentation reflects the severity of symptoms and any neurological involvement.
Comprehensive neurological examination findings and imaging results.
Patients with seizures or altered mental status following RVF infection.
Document any neurological deficits and their impact on daily functioning.
Used for confirming RVF diagnosis in symptomatic patients.
Document the clinical rationale for testing and results.
Infectious disease specialists should ensure proper interpretation of results.
Common symptoms include fever, headache, muscle pain, and in severe cases, neurological symptoms such as seizures and confusion.
Diagnosis is typically made through clinical evaluation, travel history, and laboratory testing for the presence of RVFV.
Yes, a vaccine is available and recommended for individuals at high risk, particularly those working in endemic areas.
